Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic

“…As the payments were highly skewed, negative binomial regression GEE model for the payments per physician and linear log-linked regression GEE model with Poisson distribution for the number of physicians with payments were employed. 3,4 As the national emergency concerning the COVID-19 pandemic was declared in the United States on March 13, 2020, we divided the study period into before (January 2014 to February 2020) and during the pandemic (March to December 2020). To adjust the seasonality of the payments, we included the month variable in the ITS models.…”

“…4 Average relative annual changes in per-physician payments and number of physicians receiving payments were also estimated by the GEE models with panel-data of annual payments per physician. 3 Annual trend in total payment amounts was estimated by the robust-adjusted linear regression model. As this study only included publicly available information, informed consent was waived by the Ethics Committee of the Medical Governance Research Institute.…”

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

“…Then, as previous studies repeatedly found, 16,[25][26][27] there was a significant difference in the payments between general physicians and leading physicians, namely, key opinion leaders, we performed the multivariable modified log-linked Poisson by the generalized estimating equations, as described in our previous study. 14 The Gini index was used to assess the inequality of payment distribution. 16…”

“…Trends in the total payment amounts and contracts were estimated by the generalized linear model with robust adjustment. Trends in the number of PHOs receiving payments and payments per PHO were estimated by the generalized estimating equations, as described in our previous study 14 . The Gini index was used to assess the inequality of payment distribution 16 .…”

“…However, unlike payments for clinical trials and research, personal payments such as lecturing reimbursement, consulting payments, and meal and beverages may undermine patient trust and influence physicians' treatment choices. [6][7][8][9][10][11] As oncologists and hematologists have been increasingly targeted by pharmaceutical companies over the past few years mainly reported by studies in the United States, [12][13][14] it is particularly important to properly manage financial conflicts of interest (FCOI) in order to prevent undue influence on patient care by financial interests from pharmaceutical companies and to build patients' trust among the PHOs. 15 This trend in the financial relationship between PHOs and pharmaceutical companies could also apply to the situation in Japan, the third world-largest pharmaceutical market.…”